Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Receptos to deliver scientific presentations about RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis
Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis.
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
Study hints of rituximab MS benefit
Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.
Symptom changes in multiple sclerosis following psychological interventions: a systematic review.
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Current and future disease-modifying therapies in multiple sclerosis.
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta™, for Multiple Sclerosis
Reactive astrocytes as therapeutic targets for CNS disorders.
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
Optimizing IFN Beta - 1B Dose (Optims)
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
Mitoxantrone for multiple sclerosis.

Pages